These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30168308)

  • 21. Endovascular Intervention for the Treatment of Trans-Atlantic Inter-Society Consensus (TASC) D Femoropopliteal Lesions: A Systematic Review and Meta-Analysis.
    Giannopoulos S; Lyden SP; Bisdas T; Micari A; Parikh SA; Jaff MR; Schneider PA; Armstrong EJ
    Cardiovasc Revasc Med; 2021 Jan; 22():52-65. PubMed ID: 32563709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Zilver PTX eluting stent in TASC C/D lesions and restenosis.
    Leopardi M; Houbballah R; Becquemin JP
    J Cardiovasc Surg (Torino); 2014 Apr; 55(2):229-34. PubMed ID: 24670831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
    Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
    J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(18):1-88. PubMed ID: 23074395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Effectiveness Study of Drug-Eluting and Bare-Metal Peripheral Artery Stents in Endovascular Femoropopliteal Artery Revascularization.
    Jeon-Slaughter H; Khalili H; Tsai S; Armstrong EJ; Shammas NW; Jawaid O; Lu H; Addo T; Gigliotti O; Abu-Fadel M; Banerjee S
    J Invasive Cardiol; 2018 Oct; 30(10):373-379. PubMed ID: 30279293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potential role of DES in peripheral in-stent restenosis.
    Zeller T; Macharzina R; Tepe G
    J Cardiovasc Surg (Torino); 2010 Aug; 51(4):561-5. PubMed ID: 20671640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.
    Dake MD; Ansel GM; Bosiers M; Holden A; Iida O; Jaff MR; Lottes AE; O'Leary EE; Saunders AT; Schermerhorn M; Yokoi H; Zeller T
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):8-19. PubMed ID: 31502026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.
    Ogawa Y; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
    Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1669-1677. PubMed ID: 28488101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison Between Interwoven Nitinol and Drug Eluting Stents for Endovascular Treatment of Femoropopliteal Artery Disease.
    Haine A; Schmid MJ; Schindewolf M; Lenz A; Bernhard SM; Drexel H; Baumgartner I; Dopheide JF
    Eur J Vasc Endovasc Surg; 2019 Dec; 58(6):865-873. PubMed ID: 31668949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First clinical experience with the Multi-LOC multiple stent delivery system for focal stenting in long femoro-popliteal lesions.
    Amendt K; Beschorner U; Waliszewski M; Sigl M; Langhoff R; Thalwitzer J; Redlich U; Vogel B; Härtel D; Zeller T
    Vasa; 2017 Oct; 46(6):452-461. PubMed ID: 28854856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcome of Drug-Eluted Stenting (Zilver PTX) in Patients With Femoropopliteal Occlusive Disease a Single Center Experience.
    AbuRahma AF; Beasley M; AbuRahma ZT; Davis M; Adams E; Dean LS; Shapiro J; Scott G; Davis E
    J Endovasc Ther; 2022 Jun; 29(3):350-360. PubMed ID: 34622706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
    Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
    JACC Cardiovasc Interv; 2016 Feb; 9(3):271-277. PubMed ID: 26847118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
    Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty.
    Bisdas T; Beropoulis E; Argyriou A; Torsello G; Stavroulakis K
    JACC Cardiovasc Interv; 2018 May; 11(10):957-966. PubMed ID: 29798772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
    Kichikawa K; Ichihashi S; Yokoi H; Ohki T; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
    Cardiovasc Intervent Radiol; 2019 Mar; 42(3):358-364. PubMed ID: 30411151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
    Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
    J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review and meta-analysis of balloon angioplasty versus primary stenting in the infrapopliteal disease.
    Yang X; Lu X; Ye K; Li X; Qin J; Jiang M
    Vasc Endovascular Surg; 2014 Jan; 48(1):18-26. PubMed ID: 24212407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of patency rates of self-expandable bare metal stents for endovascular treatment of femoro-popliteal arterial occlusive disease: Does stent design matter?
    Treitl KM; Woerner B; Schinner R; Czihal M; Notohamiprodjo S; Hoffmann U; Treitl M
    Eur Radiol; 2017 Sep; 27(9):3947-3955. PubMed ID: 28168366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.
    McQuade K; Gable D; Hohman S; Pearl G; Theune B
    J Vasc Surg; 2009 Jan; 49(1):109-15, 116.e1-9; discussion 116. PubMed ID: 19028055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance Study.
    Sugimoto M; Komori K; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
    J Endovasc Ther; 2021 Apr; 28(2):229-235. PubMed ID: 33084502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.